Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension (Q33710477)

28 July 2017

Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension (English)

1 reference

28 July 2017

1 reference

1 reference

1 reference

4

J Bodegard

1 reference

28 July 2017

1

S E Kjeldsen

1 reference

28 July 2017

J Stålhammar

2

1 reference

28 July 2017

P Hasvold

series ordinal

3

1 reference

28 July 2017

U Olsson

series ordinal

5

1 reference

28 July 2017

D Russell

series ordinal

6

1 reference

28 July 2017

5 November 2009

1 reference

Journal of Human Hypertension

28 July 2017

1 reference

28 July 2017

24

1 reference

28 July 2017

4

1 reference

28 July 2017

263-273

1 reference

https://scigraph.springernature.com/pub.10.1038/jhh.2009.77

28 July 2017

0 references

cites work

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2834374

Beyond the randomized clinical trial: the role of effectiveness studies in evaluating cardiovascular therapies

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2834374

Sartan-AT1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2834374

Global burden of blood-pressure-related disease, 2001.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2834374

Telmisartan, ramipril, or both in patients at high risk for vascular events

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2834374

Resource use and costs of type 2 diabetes in Sweden - estimates from population-based register data

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2834374

Design of randomized controlled trials

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2834374

Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2834374

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2834374

A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2834374

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2834374

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2834374

Update on the clinical pharmacology of candesartan cilexetil

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2834374

Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials

14 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.77

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.77

Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.77

Prevalence and incidence of Type 2 diabetes and its complications 1996-2003--estimates from a Swedish population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.77

Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.77

A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesar

21 January 2018

1 reference

12 December 2020

In vivo inhibition of angiotensin receptors in the rat kidney by candesartan cilexetil: a comparison with losartan

1 reference

12 December 2020

Blood pressure measurement--an observational study of 21 public health nurses

1 reference

12 December 2020

Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor

1 reference

12 December 2020

The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan

1 reference

12 December 2020

Association between achieving treatment goals for lipid-lowering and cardiovascular events in real clinical practice

1 reference

12 December 2020

Impact of new-onset diabetes mellitus on development of atrial fibrillation and heart failure in high-risk hypertension (from the VALUE Trial)

1 reference

12 December 2020

Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy

1 reference

12 December 2020

Identifiers

DOI

10.1038/JHH.2009.77

1 reference

Dimensions Publication ID

28 July 2017

0 references

1 reference

28 July 2017

1 reference